Autoimmune hepatitis: Pathogenesis, diagnosis and treatment

Scandinavian Journal of Gastroenterology, Supplement

Volumn 33, Issue 225 SUPPL., 1998, Pages 66-69

  Van Den Berg, A P ^a  

^a UNIVERSITY MEDICAL CENTER GRONINGEN   (Netherlands)

Author keywords

Autoimmune hepatitis; Diagnosis; Pathogenesis; Treatment

Indexed keywords

CYCLOSPORIN; IMMUNOSUPPRESSIVE AGENT; MYCOPHENOLIC ACID; TACROLIMUS;

AUTOIMMUNE HEPATITIS; CONFERENCE PAPER; EARLY DIAGNOSIS; HUMAN; LIVER CIRRHOSIS; PATHOGENESIS; PATHOPHYSIOLOGY; PRIORITY JOURNAL; REMISSION; SCORING SYSTEM; TREATMENT FAILURE; REVIEW;

HEPATITIS, AUTOIMMUNE; HUMANS;

EID: 0031600892     PISSN: 00855928     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Conference Paper

References (18)

1. Geall MG, Schoenfield LJ, Summerskill WHJ. Classification and treatment of chronic active liver disease. Gastroenterology 1972;63:458.
2. Cook GC, Mulligan R, Sherlock S. Controlled prospective trial of corticosteroid therapy in acute chronic hepatitis. Q J Med 1971;40:159.
3. Czaja AJ. Natural history, clinical features, and treatment of autoimmune hepatitis. Semin Liver Dis 1984;4:1.
4. Czaja AJ, Manns MP. The validity and importance of subtypes in autoimmune hepatitis: a point of view. Am J Gastroenterol 1995 ;90:1206.
5. Orth T, Gerken G, Kellner R, Meyer zum Buschenfelde KH, Mayet W. Actin is a target antigen of anti-neutrophil cytoplasmic antibodies (ANCA) in autoimmune hepatitis type-1. J Hepatol 1997;26:37.
6. Mulder AHL, Horst G, Haagsma EB, Limburg PC, Kleibeuker JH, Kallenberg CGM. Prevalence and characterization of neutrophic cytoplasmic antibodies in autoimmune liver diseases. Hepatology 1993;17:411.
7. McFarlane IG, Hegarty JE, McSorely CG, et al. Antibodies to liver-specific protein predict outcome of treatment withdrawal in autoimmune chronic hepatitis. Lancet 1984;2:954.
8. Czaja AJ, Carpenter HA. Sensitivity, specificity and predictability of biopsy interpretations in chronic hepatitis. Gastroenterology 1993;105:1824.
9. Johnson PJ, McFarlane IG. Meeting report: international autoimmune hepatitis group. Hepatology 1993;18:998.
10. Newton IL, Burt AD, Park JB, Matthew J, Bassendine MF, James OFW. Is the new international diagnostic scoring system for autoimmune hepatitis too rigid? Hepatology 1996;24:235A.
11. Nouri-Aria KT, Donaldson PT, Hegarty JE, et al. A1-B8-DR3 and suppressor cell function in first-degree relatives of patients with autoimmune chronic hepatitis. Hepatology 1985;1:235.
12. O'Brien CJ, Vento S, Donaldson PT, et al. Cell-mediated immunity and suppressor T cell defects to liver-derived antigens in families of patients with autoimmune chronic hepatitis. Lancet 1986;1:350.
13. Vento S, Garofano T, Di Pern G, et al. Identification of hepatitis virus A as a trigger for autoimmune chronic hepatitis type i in susceptible individuals. Lancet 1991;337:1183.
14. Vento S, Guella L, Mirandola F, et al. Epstein-Barr virus as a trigger for autoimmune hepatitis in susceptible individuals. Lancet 1995;346:608.
15. Eddleston ALWF, Williams R. Inadequate antibody response to HBAg or suppressor T-cell defect in development of active chronic hepatitis. Lancet 1974;2:1543.
16. Manns MP, Griffin KJ, Sullivan KF, et al. LKM-1 autoantibodies recognize a short linear sequence in P450 IID6. J Clin Invest 1991;88:1370.
17. Johnson PJ, McFarlane IG, Williams R. Azathioprine for long term maintenance of remission in autoimmune hepatitis. N Engl J Med 1995;333:958.
18. Crosignani A, Battezzati PM, Setchell KDR. Effects of ursodeoxycholic acid on serum liver enzymes and bile acid metabolism in chronic active hepatitis. Hepatology 1991;13:339.